Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®

NCT01392378 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 908

Last updated 2014-02-26

Study results available
· View outcomes & findings →

Summary

The purposes of this study are assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine (13vPnC) and INFANRIX hexa at 2, 3, 4 and 12 months of age when medications to prevent fever are given on the same day as the vaccination. Also to evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in children who receive medications to prevent fever on the day of vaccination.

Conditions

  • Pneumococcal Vaccines

Interventions

BIOLOGICAL

13-valent pneumococcal conjugate vaccine

13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

BIOLOGICAL

INFANRIX hexa

INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

DRUG

Paracetamol

Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.

BIOLOGICAL

13-valent pneumococcal conjugate vaccine

13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

BIOLOGICAL

INFANRIX hexa

INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

DRUG

Ibuprofen

Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.

BIOLOGICAL

13-valent pneumococcal conjugate vaccine

13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

BIOLOGICAL

INFANRIX hexa

INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

DRUG

Paracetamol

Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.

BIOLOGICAL

13-valent pneumococcal conjugate vaccine

13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

BIOLOGICAL

INFANRIX hexa

INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

DRUG

Ibuprofen

Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.

BIOLOGICAL

13-valent pneumococcal conjugate vaccine

13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

BIOLOGICAL

INFANRIX hexa

INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
56 Days
Max Age
98 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01392378 on ClinicalTrials.gov